Apellis Pharmaceuticals, Inc. — Director's Dealing 2020

Nov 18, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2020-11-16

Reporting Person: Francois Cedric (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-11-16	Common Stock	S	5000	$39.38	Disposed	1078079	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	234411	Indirect

Footnotes

F1: This is a scheduled sale from 10B5-1 trading plan.

F2: The securities are held by The Francois-DuBois Educational Trust (the "Trust"), for which the Fiduciary Trust Company of New England serves as trustee. The reporting person disclaims beneficial ownership over the shares held by the Trust except to the extent of his pecuniary interest therein.